GLP-1s
More than a dozen semaglutide generics hit the Indian market at sharp discounts post LOE for Novo Nordisk’s GLP-1 RA molecule, setting the stage for a high-octane battle in the diabetes and obesity segment. Can Novo hold steady amid the avalanche and what are KOLs looking for?
Natco has announced a 90% difference in the price of its semaglutide generic in multi-dose vials versus originator Novo Nordisk’s Ozempic pen ahead of launch tomorrow, as Novo’s patents on the product expire today. Its pen will be 70% cheaper.
Zydus’s investment in a differentiated drug-device combination for semaglutide has led to a win-win GLP-1 co-marketing deal with Lupin, even as the Indian drug regulator keeps a watch on advertising activities.
Samsung Bioepis’ explorations for an alternate semaglutide formulation will be powered by G2GBIO’s microsphere technology.
As Stada awaits the imminent closure of a deal that will see it come under the ownership of CapVest, the firm has reported 2025 sales that grew by 6% to €4.3bn, boosted by a double-digit biosimilars increase that drove Specialty sales above €1bn for the first time.
India issues firm advisory on promos for obesity and metabolic disorders therapies ahead of loss of exclusivity for semaglutide later this week, with 50-plus generic brands seen in the wings for a share of the pie. Will Eli Lilly and Novo Nordisk have to tweak their multimedia campaigns?
Biocon’s FDA approval and Cipla’s US launch – via partner Orbicular – add momentum to the early generic market for Novo Nordisk’s Saxenda.
Previously known only as AMP-007, the generic Atrovent HFA inhaler is now set for a Q2 launch with six months of exclusivity.
Sandoz says GLP-1s represent a long-term growth opportunity but warns the off-patent market will take time to develop, with early launches potentially coming in Canada and Brazil as the company tests supply dynamics and regulatory timelines.
Even Amneal, a prominent off-patent player, is not immune to generic competition, as its Parkinson’s disease drug Rytary is expected to take a hit.
Aspen Pharmacare is targeting early launches of generic semaglutide as patents begin to expire, aiming to be among the first entrants in Canada’s emerging market for GLP-1 rivals and using the approval as a springboard into emerging markets.
Hungarian pharma’s Q4 underlying profitability gain was boosted by strong CDMO activity, with steady-state profitability still targeted for 2027.
SamChunDang Pharmaceutical has penned an exclusive licensing and commercialization agreement covering generic versions of oral semaglutide products in the UK and additional European markets.
In a petition filed to HHS, non-profit Public Citizen requested the current administration to use its statutory authority to allow earlier generic competition for Novo Nordisk and Eli Lilly’s GLP-1 blockbusters.
SGLT-2 inhibitors should be used to treat patients with type 2 diabetes much earlier in their treatment, the English health technology assessment institute said, adding that using generic dapagliflozin would save the National Health Service £560m.
Biocon Biologics hinted about exploring the development of a higher concentration adalimumab biosimilar, now that it has full rights to the Hulio franchise.
A biosimilar collaboration between Kashiv and Saya aims to expand access to affordable supportive oncology therapies in Mexico and 10 additional Central America and Caribbean markets.
Sun’s founder reinforces the firm’s M&A strategy, indicating that it is "comfortable raising debt" if required, but shares no specific comment on the speculated interest in Organon. The Indian company also has "sufficient supplies" to meet demand for generic semaglutide in India post LoE.
Generics Bulletin previews the most noteworthy and anticipated events for February 2026.
A US class action suit alleges that a settlement between Teva and Novo Nordisk illegally delayed generic Victoza for 16 months, kept prices high and transferred an estimated $903m in value to Teva.